Drug repurposing in chemical genomics: Can we learn from the past to improve the future?

Current Topics in Medicinal Chemistry

Volumn 12, Issue 17, 2012, Pages 1883-1888

  Bisson, William H ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Chemical Genomics; Clinical Phase; Drug; High Throughput Screening; Repurposing; Translational Research; Virtual Ligand Screening

Indexed keywords

AURANOFIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MEVINOLIN; SILDENAFIL; VEMURAFENIB;

AMNESIA; ANGINA PECTORIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG MANUFACTURE; DRUG REPOSITIONING; GENOMICS; HUMAN; HYPERCHOLESTEROLEMIA; LEUKEMIA; NEOPLASM; NONHUMAN; STRUCTURE ACTIVITY RELATION;

DRUG REPOSITIONING; GENOMICS; PROTEINS;

EID: 84872240237     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612804547344     Document Type: Article

References (44)

1. Zanders, E.D. Overview of chemical genomics and proteomics. Methods Mol. Biol., 2012, 800, 3-10.
2. Olsen, L.C.; Faergeman, N.J. Chemical genomics and emerging DNA technologies in the identification of drug mechanisms and drug targets. Curr. Top. Med. Chem., 2012, 12, 1331-1345.
3. Roemer, T.; Davies, J.; Giaever, G.; Nislow, C. Bugs, drugs and chemical genomics. Nat. Chem. Biol., 2011, 8, 46-56.
4. Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3, 673-683.
5. Carley, D.W. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs., 2005, 8, 306-309.
6. Chong, C.R.; Sullivan, D.J. Jr. New uses for old drugs. Nature, 2007, 448, 645-646.
7. Tobinick, E.L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 2009, 22, 119-125.
8. Mullard, A. Drug repurposing programmes get lift off. Nat. Rev. Drug Discov., 2012, 11, 505-506.
9. Peterson, R.T.; Fishman, M.C. Discovery and use of small molecules for probing biological processes in zebrafish. Methods Cell Biol., 2004, 76, 569-591.
10. Zon, L.I.; Peterson, R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov., 2005, 4, 35-44.
11. Ekins, S.; Williams, A.J.; Krasowski, M.D.; Freundlich, J.S. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today., 2011, 16, 298-310.
12. Sanseau, P.; Koehler, J. Editorial: computational methods for drug repurposing. Brief Bioinform., 2011, 12, 301-302.
13. Bisson, W.H.; Cheltsov, A.V.; Bruey-Sedano, N.; Lin, B.; Chen, J.; Goldberger, N.; May, L.T.; Christopoulos, A.; Dalton, J.T.; Sexton, P.M.; Zhang, X.K.; Abagyan, R. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc. Natl. Acad. Sci. U S A., 2007, 104, 11927-11932.
14. Doan, T.L.; Pollastri, M.; Walters, M.A.; Georg, G.I. In: Annual Reports in Medicinal Chemistry; J.E. Macor, Ed.; Elsevier Science B. V: Amsterdam, 2011; Vol. 46, pp. 385-401.
15. Available from: http://de.wikipedia.org/wiki/Sildenafil/
16. Available from: http://en.wikipedia.org/wiki/Hyaluronicšacid/
17. Available from: http://en.wikipedia.org/wiki/Thalidomide/
18. Sukhai, M.A.; Spagnuolo, P.A.; Weir, S.; Kasper, J.; Patton, L.; Schimmer, A.D. New sources of drugs for hematologic malignancies. Blood, 2011, 117, 6747-6755.
19. Bisson, W.H.; Sengupta, S.; Mathew, L.K.; Kolluri, S.K.; Tanguay, R.L. Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model. Comp Biochem Physiol C Toxicol Pharmacol., 2012, 156, 121-129.
20. Kirkwood, J.S., Lebold, K.M., Miranda, C.L., Wright, C.L., Miller, G.W., Tanguay, R.L., Barton, C.L., Traber, M.G., Stevens, J.F. Vitamin C deficiency activates the purine nucleotide cycle in zebrafish. J. Biol. Chem., 2012, 287, 3833-3841.
21. Keiser, J.; Utzinger, J. Antimalarials in the treatment of schistosomiasis. Curr Pharm. Des., 2012, 18, 3531-3538.
22. Available from: http://www.tballiance.org/
23. Leung, C.H.; Chan, D.S.; Kwan, M.H.; Cheng, Z.; Wong, C.Y.; Zhu, G.Y.; Fong, W.F.; Ma, DL. Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors. ChemMedChem., 2011, 6, 765-768.
24. Keiser, M.J.; Roth, B.L.; Armbruster, B.N.; Ernsberger, P.; Irwin, J.J.; Shoichet, BK. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25, 197-206.
25. Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; Whaley, R.; Glennon, R.A.; Hert, J.; Thomas, K.L.; Edwards, D.D.; Shoichet, B.K.; Roth, B.L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-181.
26. Weir, S.J.; DeGennaro, L.J.; Austin, C.P. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res., 2012, 72, 1055-1058.
27. Available from: http://www.4cures.org/home/curesšwithinšreach.
28. Oprea, T.I.; Bauman, J.E.; Bologa, C.G.; Buranda, T.; Chigaev, A.; Edwards, B.S.; Jarvik, J.W.; Gresham, H.D.; Haynes, M.K.; Hjelle, B.; Hromas, R.; Hudson, L.; Mackenzie, D.A.; Muller, C.Y.; Reed, J.C.; Simons, P.C.; Smagley, Y.; Strouse, J.; Surviladze, Z.; Thompson, T.; Ursu, O.; Waller, A.; Wandinger-Ness, A.; Winter, S.S.; Wu, Y.; Young, S.M.; Larson, R.S.; Willman, C.; Sklar, L.A. Drug Repurposing from an Academic Perspective. Drug Discov. Today Ther. Strateg., 2011, 8, 61-69.
29. Mullard, A. Could pharma open its drug freezers? Nat. Rev. Drug Discov., 2011, 10, 399-400.
30. Available from: http://www.ncats.nih.gov/research/reengineering/rescuerepurpose/therapeutic-uses/directory.html
31. Available from: http://www.mrc.ac.uk/Fundingopportunities/Calls/MoD/compound s/index.htm
32. Alaimo, P.J., Shogren-Knaak, M.A., Shokat, K.M. Chemical genetic approaches for the elucidation of signaling pathways. Curr. Opinion Chem. Biol., 2001, 5, 360-367.
33. Dar, A.C., Das, T.K., Shokat, K.M., Cagan, R.L. Chemical genetic discovery of targets and anti-targets for cancer polipharmacology. Nature 2012, 486, 80-85.
34. Bredel, M., Jacoby, E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nature Rev. Genetics 2004, 5, 262-275.
35. Wang, L., Chiang, H.C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., Zhong, Y. Epidermal growth factor receptor is a preferred target for treating Amyloid-t-induced memory loss. Proc. Natl. Acad. Sci. U S A., 2012, in press.
36. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D.T.; Austin, C.P. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med., 2011, 3, 80ps16.
37. Lussier, Y.A.; Chen, J.L. The emergence of genome-based drug repositioning. Sci Transl Med., 2011, 3, 96ps35.
38. Available from: http://www.amazon.com/Pharmacopoeia-Peoples-Republic-China-v/dp/7117069821.
39. Lin, Y.C.; Lin, J.H.; Chou, C.W.; Chang, Y.F.; Yeh, S.H.; Chen, C.C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res., 2008, 68, 2375-2383.
40. Wang, J.C.; Chu, P.Y.; Chen, C.M.; Lin, J.H. idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucleic Acids Res., 2012, 40, 393-399.
41. Available from: http://www.nccr-chembio.ch/
42. Fishman, M. An Audience with... Nat. Rev. Drug Discov., 2012, 11, 14-15.
43. Su, E.J.; Fredriksson, L.; Geyer, M.; Folestad, E.; Cale, J.; Andrae, J.; Gao, Y.; Pietras, K.; Mann, K; Yepes, M.; Strickland, D.K.; Betsholtz, C.; Eriksson U.; Lawrence D.A. Activation of PDGFCC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med., 2008, 14, 731-737.
44. Available from: http://www.unige.ch/sciences/pharm/pb/events/